Say Goodbye to Migraines!
Say goodbye to debilitating migraines and headache attacks. Now there’s GelStat Migraine. Validated in clinical tests, and praised by customers.
GelStat Corporation is a publicly traded company trading under the symbol (“GSAC”) that is engaged in research, development, marketing and branding of innovative over-the-counter (OTC) consumer healthcare products addressing very large markets. The Company’s strategy is to grow through organic growth and strategic acquisitions.
GelStat’s products have innovative formulations combined with uniquely advantageous delivery systems that provide consumers with clinically proven products that have improved efficacy, safety and convenience. In line with this strategy, two clinical trials have been conducted on GelStat™ Migraine, both yielding positive results. The Company is presently targeting the following markets:
GelStat Migraine - Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, expects the market for migraine therapies to grow from $3.3 billion in 2011 to $5.8 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
GelStat Sleep - The total over-the-counter market for sleep aids alone reached $604 million in 2008, an increase of 9 percent over 2007, according to Packaged Facts, a division of Rockville, Md.-based Market Research Group.
Chews to Lose – According to Marketdata Enterprises, Inc., a leading independent market research publisher of “off-the-shelf” studies about service industries since 1979, an estimated 75 million dieters spent $2.7 billion in 2010 on diet pills and meal replacements.
All Natural Speed – According to an article published by Companies and markets.com, the U.S. energy drinks market is estimated to have increased by 60% over the past four years, hitting an estimated value of $12.5 billion in 2012. The industry is expected to continue this strong upward trend growing to an estimated $21.5 billion by 2017.
Joint Pain Products- GBI Research analysis shows that the global arthritis therapeutics market was estimated at $20.6 billion in 2010, during the forecast period the market grow at a Compound Annual Growth Rate (CAGR) of 7.2% between 2010 and 2018 to a market valued at $38 billion.